Purple Biotech (PPBT) Equity Average (2014 - 2026)

Purple Biotech (PPBT) has 9 years of Equity Average data on file, last reported at $9.7 million in Q1 2026.

• Quarterly Equity Average changed N/A year-over-year to $9.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.7 million (changed N/A YoY) and the FY2025 annual result came in at $21.3 million, down 36.66% from the prior year.
• Equity Average eased to $9.7 million in Q1 2026 per PPBT's latest filing, from $33.6 million in the prior quarter.
• Across five years, Equity Average topped out at $56.1 million in Q4 2022 and bottomed at $9.7 million in Q1 2026.
• The 4-year median for Equity Average is $37.2 million (2023), against an average of $35.0 million.
• The widest annual swing landed in 2023, when Equity Average slipped 27.46%; it then retreated 17.43% in 2024.
• Tracing PPBT's Equity Average over 4 years: stood at $56.1 million in 2022, then fell by 27.46% to $40.7 million in 2023, then slipped by 17.43% to $33.6 million in 2024, then slumped by 71.25% to $9.7 million in 2026.
• Per Business Quant, the three latest PPBT Equity Average figures stand at $9.7 million (Q1 2026), $33.6 million (Q4 2024), and $40.7 million (Q4 2023).

Peer Comparison